Histiocytic & Dendritic Cell Neoplasms

Histiocytic Neoplasms (macrophage lineage) Langerhans Cell Neoplasms Dendritic Cell Neoplasms Malignant / High-grade Self-limited / Indolent potential

Histiocytic Neoplasms — Macrophage Lineage

Histiocytic Neoplasms MAPK pathway · CD68+ CD163+ · macrophage derivation

Malignant histiocytic tumour

Histiocytic sarcoma

Rare · malignant · CD68+ CD163+

BRAF V600E ~30% · CD1a− · transdifferentiation from FL (shared IGH clonality) · flow unreliable · tissue IHC required

Non-Langerhans cell histiocytoses

Erdheim-Chester disease

ECD

BRAF V600E ~55%

"Hairy kidney" · coated aorta · long bone sclerosis · vemurafenib/cobimetinib first-line · foamy macrophages · Touton-like giant cells

Rosai-Dorfman disease

RDD — sinus histiocytosis with massive LAD

S100+ · CD163+ · Emperipolesis

Massive bilateral cervical LAD · KRAS/MAP2K1 · sporadic / IgG4-related / immune-related · most self-limited

Juvenile xanthogranuloma

JXG — disseminated / systemic

Non-LCH · CD163+ · Touton giant cells

Children · MAP2K1/NF1 · skin + eye + CNS in systemic · Factor XIIIa+ distinguishes from LCH · skin-limited: spontaneous regression

Langerhans Cell Neoplasms

Langerhans Cell Neoplasms CD1a+ · CD207/Langerin+ · BRAF V600E ~55% · MAPK pathway

Langerhans cell histiocytosis

LCH · unifocal / multifocal / multisystem

BRAF V600E ~55%

Coffee-bean nuclei · Birbeck granules (EM, tennis-racket) · mixed inflammatory background · vemurafenib/trametinib/cladribine · cfDNA monitoring

Langerhans cell sarcoma

LCS

Malignant LC neoplasm · high-grade · rare

Identical IHC to LCH · distinction is purely cytological (overt malignancy, necrosis, atypical mitoses) · de novo or LCH transformation · aggressive

LCH Clinical Staging: Unifocal = single bone or skin lesion · Multifocal = multiple sites same organ system · Multisystem = ≥2 organ systems · Risk organs: liver, spleen, bone marrow (SS-RO+ = poor prognosis)

Dendritic Cell Neoplasms — FDC / IDC Lineage

Dendritic Cell Neoplasms FDC / IDC / pDC lineage · rare entities

Follicular dendritic cell sarcoma

FDCS

CD21+ · CD23+ · CD35+ · Clusterin+

Storiform pattern · syncytial spindle cells · EBV+ in inflammatory/hepatic variant · CDKN2A del · NFκB pathway · surgery ± R-CHOP

Indeterminate dendritic cell tumour

IDCT

CD1a+ · CD207(Langerin)− · S100+

Phenotypically between LC and interdigitating DC · Langerin-negative is KEY · extremely rare (<50 cases) · variable prognosis · confirm Langerin negativity on fresh tissue

Shared Molecular Pathway Overview

MAPK Pathway — Unifying Driver Across All Histiocytic/DC Neoplasms

All histiocytic and DC neoplasms share MAPK pathway activation as the unifying oncogenic mechanism. BRAF V600E is the most common single activating mutation, but MAP2K1 (MEK1), KRAS, NRAS, ARAF, and other RAS-ERK pathway components are also mutated. This provides the rationale for BRAF/MEK inhibitor use across entities.

BRAF V600E ~30% · MAP2K1 · CDKN2A del · NF1 loss · TP53 del

LCH

BRAF V600E ~55% · MAP2K1 ~15% · ARAF · NRAS · ERK activated in virtually all

ECD

BRAF V600E ~55% · MAP2K1 ~10% · NRAS · PIK3CA · ARAF

RDD

KRAS G12/13 · MAP2K1 · SLC29A3 (Faisalabad spectrum) · IgG4-related subset

JXG

MAP2K1 ~30% · NF1 germline/somatic · KRAS/NRAS · BRAF V600E rare

FDCS

CDKN2A del · NFκB pathway (NFKB1, NFKBIA, TNFAIP3) · EBV (hepatic variant)

IDCT

BRAF V600E rare · MAPK involvement possible · no defining recurrent mutation

LCS

BRAF V600E (subset) · MAP2K1 · TP53 · CDKN2A del · LCH transformation

All histiocytic and dendritic cell neoplasms are diagnosed primarily by tissue IHC. Flow cytometry has limited diagnostic role. BRAF V600E IHC (VE1 clone) serves as a rapid screen but must be confirmed by molecular testing before BRAF-targeted therapy. Mixed histiocytoses (e.g., co-occurring LCH + ECD) are recognized; treat the most clinically significant component.

IHC Matrix — At a Glance

Entity	CD1a	CD207 (Langerin)	S100	CD68	CD163	Factor XIIIa	CD21/CD23/CD35	Clusterin	BRAF V600E IHC	Emperipolesis
Histiocytic sarcoma (HS)	−	−	± subset	+	+	−	−	−	± ~30%	rare
Langerhans cell histiocytosis (LCH)	+	+	+	± variable	−	−	−	−	± ~55%	−
Langerhans cell sarcoma (LCS)	+	+	+	±	−	−	−	−	± subset	−
Erdheim-Chester disease (ECD)	−	−	focal/−	+	+	+	−	−	± ~55%	−
Rosai-Dorfman disease (RDD)	−	−	+	+	+	−	−	−	−	+ CARDINAL
Juvenile xanthogranuloma (JXG)	−	−	−	+	+	+	−	−	rare	−
Follicular DC sarcoma (FDCS)	−	−	−	−	−	−	+ (triad)	+	−	−
Indeterminate DC tumour (IDCT)	+	− KEY	+	+	−	−	−	−	rare	−

Detailed IHC Panel with Tips & Pitfalls

Entity	Key IHC Panel & Notes	Additional Markers
Histiocytic sarcoma HS	CD68+CD163+Lysozyme+CD1a−CD207−CD21/CD23−S100± (subset)BRAF V600E IHC (VE1)± (~30%) ★ Flow unreliable for HS (large cells lyse). Tissue IHC required. CD68+/CD163+/Lysozyme+ without any LC, FDC, or B/T cell markers = HS. Diagnosis of exclusion requiring systematic exclusion of lymphoma, carcinoma, melanoma. ⚑ Check for shared IGH clonality with concurrent B-cell lymphoma — transdifferentiation HS has completely different therapeutic implications than de novo HS. HS arising from FL carries FL-directed therapy implications.	CD20−CD3−MPO−Clusterin− Must exclude B-cell/T-cell/myeloid/FDC lineage markers before diagnosing HS
Langerhans cell histiocytosis LCH	CD1a+CD207 (Langerin)+S100+CD68± (variable)CD21−CD23−BRAF V600E IHC (VE1 clone)± (~55%) ★ CD1a + CD207 (Langerin) = most specific IHC combination for LCH. BRAF V600E IHC (VE1 clone) positive in ~55% — rapid screen before molecular testing. Electron microscopy: Birbeck granules (tennis-racket shape) — now superseded by IHC. ★ cfDNA (plasma BRAF V600E) useful for MRD monitoring in systemic LCH. Langerin is the most specific single marker.	CD4+ (variable)CD3−Factor XIIIa− Mixed inflammatory background: eosinophils, lymphocytes, plasma cells, multinucleated giant cells are characteristic
Langerhans cell sarcoma LCS	CD1a+CD207 (Langerin)+S100+BRAF V600E IHC± ⚑ LCS vs LCH: identical IHC profile — distinction is entirely cytological (overt malignant features: large cells, marked pleomorphism, high mitotic rate, necrosis = LCS). LCS can arise de novo or transform from LCH. Never rely on IHC alone to make this distinction.	Ki-67 highp53 overexpression possible High proliferative index distinguishes from LCH on morphology context
Erdheim-Chester disease ECD	CD68+CD163+CD1a−CD207 (Langerin)−Factor XIIIa+S100 focal/−BRAF V600E IHC (VE1)± (~55%) ★ CD68+/CD163+/CD1a−/Langerin− = non-Langerhans histiocyte. Foamy macrophages + Touton-like giant cells + fibrosis. "Hairy kidney" (bilateral perirenal fat infiltration) on CT is pathognomonic. Coated aorta sign on imaging. Can co-occur with LCH (mixed histiocytosis). ★ ECD + LCH co-occurrence = mixed histiocytosis — treat as ECD+LCH combined protocol.	Lysozyme+Clusterin− Sclerotic/fibrotic background is characteristic. Touton giant cells help differentiate from RDD (which has emperipolesis not Touton cells)
Rosai-Dorfman disease RDD	S100+CD163+CD68+CD1a−CD207−Emperipolesis — lymphocytes/RBCs within histiocyte cytoplasm (cardinal) ★ S100 positivity in a non-Langerhans histiocyte is unique to RDD among non-LCH histiocytoses. Emperipolesis = intact cells within cytoplasm (not phagocytosis — cells are alive and undigested). ⚑ Emperipolesis is NOT unique to RDD — also occurs in HLH, hepatic disease, and some carcinomas. RDD diagnosis requires emperipolesis + S100+/CD163+ histiocytes in appropriate architectural context (dilated sinuses).	IgG4 (subset)Factor XIIIa− IgG4-associated RDD may coexist with IgG4-RD. Plasma cell-rich background is characteristic. Fibrous capsular thickening in LN.
Juvenile xanthogranuloma JXG	CD68+CD163+Factor XIIIa+CD1a−CD207−S100− ★ Factor XIIIa positivity distinguishes JXG from LCH. CD163+/Factor XIIIa+/CD1a−/S100− = JXG/non-LCH histiocyte lineage. S100 negative helps differentiate from RDD.	Fascin+Clusterin− Touton giant cells are pathological hallmark. Eosinophils, foamy macrophages, lymphocytes in background. Well-circumscribed dermal nodules most common.
Follicular DC sarcoma FDCS	CD21+CD23+CD35+Clusterin+CXCL13+CD68−CD1a−CD207−EBV EBER+ (inflammatory/hepatic variant) ★ CD21+/CD23+/CD35+ (FDC triad) + Clusterin = signature IHC profile of FDCS. Clusterin is highly sensitive for FDC lineage. Inflammatory FDCS (hepatic/abdominal): EBV+ in majority — mimic of giant cell hepatocellular carcinoma, but EBV-EBER+ and FDC markers confirm. ⚑ FDCS in the liver can closely mimic giant cell hepatocellular carcinoma. Always include FDC markers (CD21/CD23/CD35/Clusterin) and EBV-EBER in the workup of unusual hepatic tumors with inflammatory stroma.	Podoplanin (D2-40)+Vimentin+CD68− Spindle cell morphology. Lymphocytic cuffing around vessels is a distinctive feature. Syncytial cytoplasm with indistinct borders.
Indeterminate DC tumour IDCT	CD1a+S100+CD207 (Langerin)− ← KEYCD21−CD23−CD68+ ★ CD1a+/S100+/Langerin− = IDCT. CD207/Langerin negativity is the KEY feature distinguishing IDCT from LCH (which is CD1a+/S100+/Langerin+). Represents a DC phenotypically between a Langerhans cell and an interdigitating DC. ⚑ IDCT is extremely rare — before diagnosing, confirm Langerin (CD207) negativity on multiple IHC sections and on fresh material if possible. Focal/weak Langerin on degraded tissue should NOT be used to reclassify IDCT as LCH.	Birbeck granules absent (EM) No Birbeck granules on EM — key ultrastructural distinction from LCH. Skin and lymph node most common sites.

Key IHC discriminator panel: CD1a + CD207/Langerin → LCH/LCS · CD21/CD23/CD35/Clusterin → FDCS · CD68/CD163/Lysozyme + CD1a−/CD207− → HS, ECD, RDD, JXG · S100 positive in LCH, LCS, RDD, IDCT; negative or focal in HS, ECD, JXG · BRAF V600E IHC (VE1 clone) → LCH, ECD, HS, LCS (subset) · Emperipolesis + S100 + CD163 → RDD · Touton giant cells + Factor XIIIa → JXG/ECD · Flow cytometry has limited role — all diagnoses primarily by tissue IHC.

Entity	Morphological Hallmarks	Distinctive Features / Pitfalls	Specimen & Architecture
Malignant Histiocytic Tumours
Histiocytic sarcoma (HS)	Sheets of large pleomorphic cells Vesicular nuclei · Prominent eosinophilic nucleoli Abundant pink/eosinophilic cytoplasm Phagocytic vacuoles (emperipolesis rare) Brisk mitoses · No specific granules	⚑ No pathognomonic morphological feature — diagnosis requires IHC exclusion of LC, FDC, B/T/myeloid lineage ★ Transdifferentiation HS (from FL) may retain areas of follicular architecture — check for concurrent lymphoma	Lymph node (sinusoidal or diffuse effacement), spleen, skin, soft tissue · LN architecture effaced in diffuse pattern or sinusoidal infiltration · Extranodal sites common
Langerhans cell sarcoma (LCS)	Same lineage markers as LCH but overtly malignant cytology Marked nuclear pleomorphism Frequent prominent nucleoli High mitotic rate · Atypical mitoses Necrosis · Large cell size Loss of subtle "coffee-bean" nuclear fold seen in LCH	⚑ IHC identical to LCH — LCS is a cytological diagnosis. The "coffee-bean" groove of LCH is LOST in LCS due to overt malignancy ★ Can arise de novo or from transformation of established LCH	Lymph node, skin, liver, lung · Extranodal involvement common · Necrosis often present in advanced disease
Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH)	"Coffee-bean" / reniform nuclei — longitudinal nuclear groove or fold Medium-to-large cells · Fine chromatin Inconspicuous nucleolus Abundant pale eosinophilic cytoplasm Mixed inflammatory background: eosinophils, lymphocytes, plasma cells, multinucleated giant cells Necrosis in aggressive forms Birbeck granules on EM (tennis-racket shape) — now superseded by IHC	★ Eosinophils in the background are a classic associated finding — especially in bone LCH (eosinophilic granuloma) ⚑ The "coffee-bean" groove is subtle and may be difficult to appreciate in poorly fixed tissue. Rely on CD1a/Langerin IHC for confirmation. ⚑ In aggressive LCH, the grooves can be partially obscured by pleomorphism — use IHC	Bone (most common unifocal), skin, LN, lung, liver, spleen, pituitary (diabetes insipidus in multisystem) · Lung LCH: stellate nodules along bronchovascular bundles · Bone: lytic lesion, often punched-out on X-ray
Non-Langerhans Histiocytoses
Erdheim-Chester disease (ECD)	Foamy macrophages — large cells with pale vacuolated cytoplasm Touton giant cells — wreath of nuclei surrounding central eosinophilic granular zone (radial/asteroid arrangement) Background fibrosis (xanthogranulomatous reaction) Infiltration of orbital fat, bone, retroperitoneum, perirenal fat, aortic wall	★ "Hairy kidney" on CT (bilateral perirenal fat infiltration) is pathognomonic — the foamy histiocytes infiltrate the perirenal fat creating this radiological sign ★ Coated aorta sign = circumferential periaortic fibrosis on CT ⚑ Can co-occur with LCH — always check IHC for CD1a/Langerin in ECD to exclude mixed histiocytosis	Multi-systemic: bone (bilateral symmetric long bone sclerosis), retroperitoneum, perirenal fat, aorta, orbit, CNS, pericardium · Bone lesions: osteosclerotic (vs LCH which is lytic) · Long bones: distal metaphysis/diaphysis
Rosai-Dorfman disease (RDD)	Dilated sinuses packed with large pale S100+ histiocytes Emperipolesis (CARDINAL): lymphocytes and/or RBCs intact within histiocyte cytoplasm (surrounded by clear halo) Fibrous capsular thickening Plasma cell-rich background Lymph node architecture partially preserved	★ Emperipolesis ≠ phagocytosis. In emperipolesis, engulfed cells are ALIVE and undigested. In phagocytosis, cells are dead and digested. The clear halo around engulfed cells is the histological clue. ⚑ Emperipolesis also occurs in HLH, hepatic disease, and some carcinomas. Context + S100+/CD163+ + dilated sinuses are required for RDD diagnosis. ⚑ Extranodal RDD (CNS, skin, soft tissue) may lack dilated sinuses — still S100+/CD163+ with emperipolesis	Lymph node most common (massive bilateral cervical LAD) · Extranodal sites: CNS (intracranial, dural), skin, soft tissue, bone, nasal cavity · LN: sinusoidal expansion, preserved architecture (vs HS which effaces)
Juvenile xanthogranuloma (JXG)	Touton giant cells (HALLMARK): wreath of nuclei arranged around central foamy/eosinophilic zone, surrounded by outer rim of foamy xanthomatized cytoplasm Background: lymphocytes, eosinophils, foamy macrophages Well-circumscribed dermal nodule No Birbeck granules · No coffee-bean nuclear grooves	★ Touton giant cells are also seen in ECD — use IHC (Factor XIIIa+/CD163+ for JXG vs same plus BRAF V600E+ for ECD) ★ Early lesions may have pure histiocytic infiltrate without Touton cells — use IHC panel ⚑ Systemic JXG in infants: orbital, CNS, liver involvement — different prognosis than skin-limited JXG which regresses spontaneously	Skin (most common): well-circumscribed nodule in dermis · Systemic JXG: orbit, CNS, liver, spleen, soft tissue · Eye involvement can cause glaucoma/blindness · NF1 germline → higher risk of systemic JXG + JMML
Dendritic Cell Neoplasms
Follicular DC sarcoma (FDCS)	Storiform (whorling) or fascicular growth pattern Syncytial sheets of oval-to-spindle cells Indistinct cell borders ("syncytial cytoplasm") Vesicular nuclei · Small nucleolus Lymphocytic cuffing around vessels and percolating between tumor cells Mild-to-moderate nuclear atypia · Binucleate/multinucleate forms Inflammatory FDCS (hepatic): dense lymphoid stroma, EBV+ tumor cells, abundant TILs	⚑ Inflammatory FDCS (hepatic/abdominal) mimics giant cell hepatocellular carcinoma — check EBV-EBER and FDC markers (CD21/CD23/CD35/Clusterin) in all unusual hepatic spindle cell tumors ★ Lymphocytic cuffing around vessels is a distinctive feature that helps identify FDCS even when morphology is ambiguous	Lymph node (most common) · Extranodal: liver/abdomen (inflammatory variant), tonsil, soft tissue, spleen · Storiform pattern in LN: sheets of spindled cells replacing nodal architecture · Hepatic FDCS associated with Castleman disease in some cases
Indeterminate DC tumour (IDCT)	Similar to LCH morphologically: medium-to-large cells, pale cytoplasm, folded/irregular nuclei LACKS the characteristic "coffee-bean" nuclear groove of LCH Mixed inflammatory background No Birbeck granules on EM Variable atypia	⚑ IDCT is a diagnosis that requires Langerin (CD207) negativity confirmed on fresh material — degraded tissue may give false negative Langerin. Cannot distinguish IDCT from LCH on morphology alone. ★ Skin and lymph node are the most common sites. Represents a DC that has undergone partial Langerhans differentiation without acquiring Birbeck granule formation.	Skin and lymph node most common · Extremely rare entity (<50 cases reported) · Variable prognosis

Morphological assessment must be performed on well-fixed, adequately processed tissue. All histiocytic diagnoses require IHC confirmation — morphology alone is insufficient for a definitive diagnosis. EM (for Birbeck granules in LCH) has been largely superseded by Langerin IHC.

MAPK Pathway Mutations — By Entity

Entity	Primary Mutations	Secondary / Co-occurring	Therapeutic Targets	Special Considerations
Histiocytic Neoplasms (Macrophage Lineage)
Histiocytic sarcoma (HS)	BRAF V600E ~30%MAP2K1NF1 loss	CDKN2A delTP53 del	BRAF V600E+ → vemurafenib/cobimetinib · MEK inhibitors (trametinib) · Gemcitabine-based regimens (no standard) · alloSCT for eligible patients	★ De novo HS vs transdifferentiation HS (from FL) have COMPLETELY DIFFERENT biology. Always check for shared IGH clonality. Transdifferentiation HS may respond to FL-directed therapy. ⚑ Very rare · No standard systemic therapy established · Trial enrollment recommended
Erdheim-Chester disease (ECD)	BRAF V600E ~55%MAP2K1 ~10%NRASPIK3CA	ARAFKRAS	BRAF V600E+ → Vemurafenib (FDA-approved for BRAF V600E+ ECD) · Cobimetinib (MEK inhibitor) · Anakinra (IL-1R antagonist) for BRAF-WT · Pegylated IFN-α2a (historical, BRAF-WT) · Trametinib for MAP2K1	★ Vemurafenib is FDA-approved specifically for BRAF V600E+ ECD — this is the first approved therapy for this disease. BRAF testing is mandatory before treatment. ★ ECD can co-occur with LCH (mixed histiocytosis) — treat as ECD+LCH combined protocol
Rosai-Dorfman disease (RDD)	KRAS G12/13 (sporadic)MAP2K1SLC29A3 mut (Faisalabad)	IgG4-associated subset	Most sporadic RDD → observation (self-limited) · IgG4-related: steroids/rituximab · MAPK-mutated: targeted BRAF/MEK inhibitors · Rare transformation to HS	★ SLC29A3 mutations cause Faisalabad histiocytosis / H syndrome spectrum — a distinct familial syndrome with RDD-like pathology ⚑ IgG4-associated RDD may coexist with true IgG4-RD — check IgG4 plasma cell density and IgG4/IgG ratio in the histiocytic lesion and in surrounding tissue
Juvenile xanthogranuloma (JXG)	MAP2K1 ~30%NF1 germline/somaticKRAS/NRAS subset	BRAF V600E rare	Skin-limited JXG → spontaneous regression (observation) · Systemic JXG → vinblastine/prednisone · CNS involvement → CNS-directed therapy · Trametinib for MAP2K1-mutated refractory	★ NF1 germline association — patients with NF1 syndrome have higher risk of systemic JXG and concurrent JMML. Screen for JMML in NF1 + JXG patients <2 years old.
Langerhans Cell Neoplasms
Langerhans cell histiocytosis (LCH)	BRAF V600E ~55%MAP2K1 ~15%ARAFNRAS	ERK pathway activated in virtually all LCH	Unifocal bone → curettage/RT · Multifocal/multisystem → cladribine + cytarabine · BRAF V600E+ systemic → vemurafenib/cobimetinib · MEK inhibitor (trametinib) for BRAF-WT MAPK-driven · cfDNA (plasma BRAF V600E) for MRD monitoring	★ cfDNA monitoring of plasma BRAF V600E is a major advance — allows non-invasive disease monitoring and early detection of relapse in BRAF V600E+ systemic LCH ★ ERK pathway activation is the unifying feature of ALL LCH — even BRAF-WT cases have activation through MAP2K1/NRAS/ARAF mutations ⚑ Risk stratification: SS+ (spleen, liver, BM) = high-risk multisystem LCH. SS-RO+ = single system risk organ positive = poor prognosis requiring intensified therapy
Langerhans cell sarcoma (LCS)	BRAF V600E subsetMAP2K1TP53CDKN2A del	Additional driver mutations vs LCH due to malignant transformation	Chemotherapy ± targeted BRAF/MEK inhibitors · No standard therapy · Very aggressive · alloSCT if eligible	⚑ LCS can arise de novo or transform from LCH. Transformation associated with additional TP53 mutations and CDKN2A deletions on top of original BRAF V600E or MAP2K1 driver
Dendritic Cell Neoplasms
Follicular DC sarcoma (FDCS)	CDKN2A delNFKB1 mutNFKBIA mutTNFAIP3 mut	EBV+ (hepatic/inflammatory variant)	Surgery for localized · Gemcitabine/docetaxel or R-CHOP for advanced · No standard systemic therapy · 10–20% metastatic rate · Local recurrence common · EBV-FDCS (hepatic): may be more indolent	★ FDCS does NOT share the MAPK pathway biology of other histiocytic neoplasms — NFκB pathway is the primary driver ★ EBV-associated FDCS (hepatic) has a distinct biology — EBV is a driver in tumor cells (not bystander). May be more indolent than conventional FDCS.
Indeterminate DC tumour (IDCT)	BRAF V600E rareMAPK involvement possible	No defining recurrent mutation established · Clonal IG/TCR rearrangements rare	Surgery for localized · Systemic therapy if disseminated (no standard) · Variable prognosis	⚑ Extremely rare entity (<50 cases reported) — limited molecular data available. Management is largely extrapolated from other histiocytic neoplasms.

Treatment Summary by BRAF Status

BRAF V600E+ Entities

LCH: Vemurafenib/cobimetinib · Trametinib (BRAF-WT MEK-driven)
ECD: Vemurafenib (FDA-approved 1st line) · Cobimetinib
HS: Vemurafenib/cobimetinib (case reports)
LCS: BRAF/MEK inhibitors ± chemo

BRAF V600E IHC (VE1 clone) as rapid screen, confirm by sequencing before targeted therapy

BRAF V600E− (MAPK-driven) or BRAF-WT

MAP2K1-mutated: Trametinib/cobimetinib (MEK inhibitors)
ECD BRAF-WT: Anakinra (IL-1R antagonist) · PEG-IFN-α2a
RDD KRAS-mutated: MEK inhibitors emerging data
JXG MAP2K1: Trametinib for refractory systemic disease

Comprehensive MAPK pathway mutation testing (NGS) recommended when BRAF V600E negative

Molecular testing strategy: BRAF V600E IHC (VE1 clone) → rapid screen. If IHC positive, confirm by sequencing (Sanger or NGS) before initiating targeted therapy. If IHC negative, proceed to comprehensive NGS panel covering BRAF, MAP2K1, KRAS, NRAS, ARAF, PIK3CA, and other MAPK pathway genes. cfDNA (liquid biopsy) for BRAF V600E useful for disease monitoring in multisystem LCH and ECD.

Critical IHC Discriminator Pairs

LCH vs IDCT

Both: CD1a+ · S100+ · skin/LN involvement
LCH: CD207/Langerin+ + Birbeck granules (EM) + "coffee-bean" nuclei
IDCT: CD207/Langerin− ← KEY + No Birbeck granules + loses "coffee-bean" groove

⚑ Langerin must be confirmed on fresh/well-fixed tissue — degraded tissue may give false-negative Langerin, erroneously suggesting IDCT

LCH vs LCS

Both: CD1a+ · Langerin+ · S100+ — identical IHC profile
LCH: Bland cytology · "coffee-bean" nuclei · low mitotic rate · no necrosis
LCS: Overt malignant cytology · marked pleomorphism · high mitotic rate · atypical mitoses · necrosis · loss of "coffee-bean" groove

★ The distinction is purely cytological/histological — IHC cannot separate these two entities

RDD vs LCH (S100 overlap)

Both: S100+
RDD: CD1a− Langerin− + emperipolesis + dilated sinuses + massive cervical LAD
LCH: CD1a+ · Langerin+ · coffee-bean nuclei · mixed inflammatory (eosinophils)

⚑ S100 positivity in a non-Langerhans histiocyte = think RDD. S100 in context of CD1a+/Langerin+ = LCH

HS vs Diffuse Large B-Cell Lymphoma

Both: Large cell morphology · LN effacement · aggressive clinical course
HS: CD68+ · CD163+ · Lysozyme+ · CD20− · CD3− · PAX5−
DLBCL: CD20+ · PAX5+ · OCT2+ · BOB1+ · negative macrophage markers

⚑ HS can arise from transdifferentiation of FL — always check IGH clonality and concurrent B-cell lymphoma. Check CD20 on HS even if focally residual.

JXG vs LCH (Touton giant cells)

Both: Skin/systemic involvement · inflammatory infiltrate
JXG: Factor XIIIa+ CD1a− S100− + Touton giant cells
LCH: CD1a+ · Langerin+ · S100+ · "coffee-bean" nuclei · eosinophils

★ Factor XIIIa+ is the discriminating marker. Touton giant cells occur in both JXG and ECD but not LCH.

ECD vs JXG (Touton giant cells overlap)

Both: Touton giant cells · foamy macrophages · Factor XIIIa+/CD163+
ECD: Multi-systemic · long bone sclerosis · "hairy kidney"/coated aorta · BRAF V600E ~55% · perirenal fat infiltration
JXG: Children · skin-limited or orbital/CNS · MAP2K1 ~30% · spontaneous regression possible

★ Clinical presentation, radiology, and age are key discriminators. Molecular testing (BRAF for ECD, MAP2K1 for JXG) aids classification.

FDCS vs Spindle Cell Tumors

FDCS: CD21+ · CD23+ · CD35+ · Clusterin+ · lymphocytic cuffing · storiform pattern · EBV+ hepatic variant
Mimics: Inflammatory myofibroblastic tumor (ALK+), solitary fibrous tumor (STAT6+), follicular dendritic cell pseudotumor (no CD21/23/35)

⚑ Hepatic FDCS (EBV+) is the greatest mimic of giant cell hepatocellular carcinoma. Always include Clusterin/CD21/CD23 in hepatic spindle cell tumor workup.

RDD Emperipolesis vs HLH Hemophagocytosis

Both: Histiocytes engulfing hematopoietic cells · may present with cytopenias
RDD emperipolesis: Engulfed cells ALIVE (clear halo) · S100+/CD163+ histiocytes · dilated sinuses in LN · massive LAD
HLH hemophagocytosis: Engulfed cells DEAD/digested · CD68+/CD163+ · fever, splenomegaly, ferritin >500 · cytokine storm context

★ In RDD, the "engulfed" lymphocytes/RBCs have an intact membrane and clear halo. In HLH, the engulfed cells are degraded without the clear halo.

Algorithmic IHC Approach to Histiocytic Neoplasm

Step 1: Confirm histiocytic lineage — CD68+ · CD163+ · Lysozyme+
Step 2: Apply the LC screen — CD1a + CD207 (Langerin)
   → CD1a+ / Langerin+ = LCH or LCS (distinguish by cytology: overt malignancy = LCS)
   → CD1a+ / Langerin− = IDCT (confirm Langerin on fresh tissue)
Step 3: Apply the FDC screen — CD21 + CD23 + CD35 + Clusterin
   → FDC triad+ = FDCS
Step 4: Non-LC, non-FDC histiocyte — further panel:
   → S100+ / Emperipolesis = RDD (dilated sinuses, cervical LAD)
   → Foamy macrophages / Touton / BRAF V600E+ / bilateral long bone sclerosis = ECD
   → Factor XIIIa+ / S100− / children / skin nodule = JXG
   → Large pleomorphic cells / aggressive / exclusion of all above = HS
Step 5: BRAF V600E IHC (VE1 clone) — screen all entities. Confirm positive results by molecular testing before targeted therapy.

High-Yield Exam Facts

LCH signature: CD1a+ · Langerin+ · S100+ · "coffee-bean" nuclei · BRAF V600E ~55% · eosinophils in background · Birbeck granules (EM)

ECD signature: "Hairy kidney" (pathognomonic on CT) · coated aorta · foamy macrophages · Touton giant cells · long bone sclerosis (osteosclerotic)

RDD signature: Emperipolesis (alive cells in histiocyte cytoplasm) · S100+ non-LC histiocyte · massive bilateral cervical LAD · dilated sinuses

JXG signature: Touton giant cells · Factor XIIIa+ · S100− (unlike RDD) · children · skin-limited spontaneous regression · NF1 association

FDCS signature: CD21/CD23/CD35 triad + Clusterin · storiform spindle cells · lymphocytic cuffing · EBV+ hepatic variant (mimics hepatocellular carcinoma)

IDCT signature: CD1a+ · Langerin− (KEY) · S100+ · no Birbeck granules · phenotypically between LC and interdigitating DC · extremely rare

HS pitfall: Always check for transdifferentiation from FL (shared IGH clonality). Flow cytometry unreliable — tissue IHC required. Diagnosis of exclusion.

BRAF V600E testing: IHC (VE1 clone) as rapid screen in LCH, ECD, HS, LCS. Always confirm positive IHC by molecular sequencing before initiating vemurafenib/cobimetinib.

Universal panel for all histiocytic/DC neoplasms: CD1a + CD207/Langerin + S100 + CD68 + CD163 + CD21 + CD23 + CD35 + Clusterin + Factor XIIIa + BRAF V600E IHC (VE1) · Additional: Lysozyme, EBV-EBER, Ki-67 · Electron microscopy for Birbeck granules (now historical — superseded by Langerin IHC) · Flow cytometry has limited role — all diagnoses primarily by tissue IHC.